Murali Aravamudan, Co-Founder and CEO of nference, joins Dr. Jonathan Piccini for a visionary main tent conversation exploring how artificial intelligence is redefining cardiovascular medicine. A serial entrepreneur and engineer with a track record of building transformative technology companies, Murali has turned his focus to life sciences through nference and its affiliated ventures, leveraging AI to make biomedical knowledge computable at unprecedented scale.

Together, Murali and Dr. Piccini will examine how massive multimodal datasets—from electronic health records to imaging, genomics, and physiologic signals—are enabling a new era of predictive and precision cardiovascular care. The discussion will explore the intersection of AI, electrophysiology, and translational innovation, including how partnerships between technology companies, health systems, and clinicians can accelerate discovery and improve patient outcomes. Attendees will gain insight into the opportunities and challenges of implementing AI in real-world practice, the evolving role of data-driven medicine, and what the next decade of intelligent cardiovascular care may look like.

Artificial intelligence is reshaping how we detect, diagnose, and manage arrhythmias—but what is the role of digital transformation in achieving sustainable healthcare delivery? This session unpacks the promise and the challenges of AI in heart rhythm care, from wearable devices that flag arrhythmias in real time to decision-support algorithms that guide risk assessment and personalized therapy. Participants will discuss common pitfalls (including bias, data privacy, and workflow integration) and explore practical ways to harness AI tools for patient care, device management, and interprofessional collaboration. Whether you’re a nurse, technician, pharmacist, or physician assistant, you’ll gain the knowledge and confidence to critically evaluate new technologies, optimize patient outcomes, and become a champion for responsible innovation in your clinical setting.

Managing the influx of ILR transmissions requires a delicate balance between sensitivity and workflow efficiency. This roundtable will explore the frontline battle against data deluge, debating the efficacy of built-in manufacturer algorithms versus integrated third-party platforms. Panelists will share insights on how to streamline triage workflows and identify the most effective strategies for actionable cardiac monitoring.

Continuous rhythm monitoring paired with a patient-facing app turns a single diagnostic episode into an always-on platform. Imagine 24/7 access to quantified rhythm data, raw ECG, and patient-reported input — symptoms, wellbeing, adherence — in one stream. The question this roundtable puts to the room: with that foundation in place, what would you build?

What does the future of AFib care actually look like? Strong evidence supports early rhythm control, but adoption remains inconsistent due to gaps in execution, coordination, and access. This roundtable will explore how to translate evidence into scalable, real-world care delivery.

Most MedTech failures happen before first-in-human, not because of bad technology, but because of the wrong preclinical strategy. Startups often overspend on data that doesn’t reduce regulatory risk or move them closer to clinical use. In this session, you’ll learn how to align preclinical, simulation, and regulatory strategy to move faster with less waste.

Remote monitoring was originally designed to detect device problems. Today it has the potential to become the digital backbone for managing atrial fibrillation, heart failure, hypertension, obesity, sleep apnea, and post-procedure follow-up. This discussion explores how health systems can build integrated, longitudinal care pathways that combine remote monitoring, patient engagement, AI, and care navigation into a single operating model.

The HRX 2026 Pitch Competition provides cardiovascular startups with a platform to present their innovative products, services, and solutions to a distinguished panel of judges and potential investors and win cash prices. The top five teams selected will compete on the HRX Main Stage. Each team will have ~5-10 minutes to creatively pitch their innovative idea, followed by five minutes to field questions from judges and attendees.

Arrhythmia care is often a necessity—but not all patients have equal access to cutting-edge treatments, timely diagnoses, or educational resources. In this interactive session, allied professionals will explore the barriers faced by underserved communities—including rural, low-income, and minority populations—in accessing effective heart rhythm care. We will discuss the role of the allied professional in leveraging telehealth, mobile clinics, wearable technology, community education, and culturally sensitive care models.

As the management of supraventricular tachycardia (SVT) evolves, advances in drug development, digital health technologies, and patient-centered care are reshaping the acute treatment pathway. This interactive
roundtable will explore how emerging therapies, innovative outpatient management strategies, and integration with wearable technologies may improve patient outcomes, optimize healthcare utilization, and redefine the transition from symptom relief to definitive arrhythmia care.

What happens when electrophysiologists, engineers, and entrepreneurs co-design the future of arrhythmia care? This session will highlight how the HRS Research Network is enabling large-scale collaborative studies, advancing AI and digital twin models, and leveraging data infrastructure—from clinical trials like CABANA-HF to real-world ECG, EHR, and registry-based analytics—to accelerate discovery and innovation. Join us to explore how to engage with this ecosystem and translate cutting-edge technologies into impactful clinical research and practice.

AI is rapidly entering EP labs but its real test is whether it can standardize complex workflows and expand access to care. This roundtable separates hype from impact and explores how AI-enabled pathways can help find, refer, and treat the complex AF patients who make up the “untreated majority.” The discussion will also examine how reimbursement and coverage considerations influence the adoption, scalability, and patient access of these emerging technologies.

The session will explore the evolving role of autonomic neuromodulation as a complementary strategy to traditional ablation and pharmacologic therapies for complex, recurrent arrhythmias. Panelists will discuss emerging approaches, with particular focus on the potential for beneficial effects of sympathetic pathway attenuation at the level of ansa subclavia, a nerve bundle in the paravertebral sympathetic chain, highlighting its promise for reducing arrhythmia recurrence and addressing current limitations of existing therapies.

This session will examine the next wave of ambulatory ECG monitoring technologies designed to address the diagnostic, workflow, and patient-experience gaps that persist despite the maturation of patch-based and implantable solutions. Faculty will discuss where current options fall short for key patient populations (e.g. cryptogenic stroke, recurrent unexplained syncope, low-yield palpitation workups) and what device, signal-quality, and integration requirements must be met before a new option can earn a place in the standard EP toolkit.

Cardiac genetics offers a compelling test case for digitally enabled precision medicine—where the convergence of genomics and continuous data has the potential to fundamentally reshape how risk is understood, monitored, and managed. This session will explore these themes as well as the potential for interventional therapies that can fundamentally change outcomes.

Rebecca Seidel, Senior Vice President and President of Cardiac Ablation Solutions at Medtronic, joins Dr. Suneet Mittal for a dynamic main tent conversation focused on what it takes to scale innovation in one of the fastest-growing sectors in MedTech. With more than two decades of leadership experience and oversight of a billion-dollar global business, Rebecca has led major acquisitions, accelerated innovation pipelines, and driven the commercialization of transformative cardiac technologies.

Together, Rebecca and Dr. Mittal will explore how organizations can successfully bridge the gap between breakthrough concepts and real-world clinical impact. The discussion will examine the strategic decisions behind building and integrating innovation, navigating market disruption, fostering high-performing teams, and shaping the future of cardiac ablation technologies. Attendees will gain insight into leadership at scale, the evolving competitive landscape in electrophysiology, and how industry leaders are positioning the next generation of therapies to improve outcomes for patients worldwide.

This discussion explores how socially assistive robotics (“social robotica”) can enhance patient education by delivering consistent, personalized, and engaging coaching at the bedside, in clinics, and at home. We’ll review current use cases (e.g., medication adherence, rehab support, patient information, risk factor and lifestyle modification, chronic disease self-management), what the evidence says about patient outcomes and equity, and how robots can integrate with care teams and digital health tools. Participants will discuss practical design and implementation considerations—workflow fit, accessibility, privacy, trust, and safety—and leave with a framework for evaluating where social robots add real value in integrated care.

We will discuss all the latest research on ECG metrics to optimize LBBA pacing implants and follow up.

Catheter-based treatment of cardiac arrhythmias and Left Atrial Appendage Occlusion has seen tremendous advances in the past decade, lastly with a stronger trend toward integrated concomitant procedures. With evolving clinical needs and interventional workflows, the community continues to aim at improved efficacy, efficiency and safety for patients and staff, ultimately leading to the best treatment across complex patient populations. For Intraprocedural guidance as a cornerstone enabling understanding and navigating within the human anatomy, main modalities of choice today are Electro anatomical Mapping (EAM) and Intracardiac Echocardiography (ICE) for ablation, as well as Fluoroscopy and Transesophageal Echocardiography (TEE) for Left Atrial Appendage Occlusion. With a continued trend toward fully anatomically guided ablation approaches with modern PFA ablation systems, as well as concomitant treatment of LAAC, this session aims to discuss strategies and innovative technologies to enable individual and combined workflows through interventional cardiac image guidance using ICE. A specific focus here is to review where today’s workflows are challenged using different guidance solutions as well as the trend toward more integrated and combined procedures, and the need for reliable, intuitive, and precise navigation as a key requirement for optimal treatment.

Many MedTech companies generate clinical data and still fail to gain traction because their evidence does not align with how care is actually delivered, evaluated, and paid for. Health systems, physicians, and
administrators are not asking for more data, they are asking for clarity on outcomes, workflow impact, and economic value. This roundtable brings together provider, regulatory, and clinical strategy perspectives to unpack why evidence fails to influence real decisions and what it takes to build a case that drives use in practice.

Cardiac electrophysiology is sitting on an unprecedented volume of data from CIEDs, remote monitoring platforms, EHRs, and registries, and AI promises to transform how we make sense of it. Yet the gap between algorithmic capability and real-world clinical adoption remains stubbornly wide, and closing it demands honest conversation about data quality, equity, and operational readiness. This roundtable brings together clinicians, researchers, and industry innovators to challenge assumptions, surface blind spots, and define what it will actually take to move AI from promising to practice.

Explore the reconciliation of time associated with the 32 tasks outlined in the HRS consensus statement on remote monitoring, with a specific focus on the realities of advanced practice provider workflows in EP clinics. This discussion will examine how time is distributed across these tasks, where hidden or unreimbursed work occurs, and how clinics can better define, measure, and align APP effort with operational and clinical expectations. Participants will share practical strategies for workload assessment, role optimization, and staffing models that support efficient, high-quality remote monitoring programs while recognizing the critical contribution of APPs.

In the medical device space, risk-reward sharing partnerships are uncommon for technology and clinical evidence development. AVIM therapy provides a unique case study on the benefits of such collaboration in bringing new innovations to market.

The methods for AI-interpretation of electrocardiograms and other biosignatures are now well-established. However, implementing them in clinical practice is often an uphill battle. Cutting edge AI technologies that can predict incident atrial fibrillation or the onset of cardiomyopathy have tremendous value . . . but only if they are implemented and impact the patients they have been designed to help. This session moves beyond the individual AI-ECG tools and technologies themselves and focuses on how we can innovate care by putting these tools into everyday clinical practice. The session will foster a vibrant discussion of the challenges, opportunities, and best practices for bringing the power of AI-ECG technologies to all patients.

Mobile cardiac telemetry and near-real-time analytics offer clinical value that remains underused. But recommending real time analysis for every patient produces alert fatigue, unnecessary cost, and noise that erodes clinician trust, while defaulting to retrospective analysis risks missing the signals that demand same-day action. This session asks where real-time monitoring meaningfully changes care, where Holter and extended Holter studies remain the better choice, and what medical-grade analytics, and notification configurations must deliver to make real-time something clinicians can trust and act on. This roundtable reframes real-time versus retrospective monitoring from a winner-take-all debate into a more useful question: which approach fits which clinical scenario. Bringing electrophysiologists, general cardiologists, and technologists together, we will map where true near-real-time mobile cardiac telemetry delivers value that Holter and extended-Holter studies cannot, and where the established approaches remain appropriate. We will then confront the requirement that determines whether MCT’s promise is realized in practice: medical-grade, validated analytics that deliver accuracy and actionable insight at scale, and workflow practices that keep alert fatigue from undermining adoption.

Patients arrive in the electrophysiology lab carrying diagnoses we can see and conditions we often cannot. Heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis (CA) frequently hide behind a presentation of atrial fibrillation, yet both reshape the atrial substrate, the thromboembolic profile, and the durability of the rhythm-control strategies we offer. This roundtable asks a deceptively simple question: if we identified these conditions earlier, before the ablation or the appendage closure, would we make better procedural decisions and achieve better outcomes for our patients?
Using Ultromics’ FDA-cleared EchoGo® platform, which detects HFpEF and cardiac amyloidosis from a single, routinely acquired echocardiographic view, the panel will work through how earlier phenotyping could refine candidate selection, pre-procedure patient management, periprocedural planning, and anticoagulation strategy for AF ablation and LAAC. The discussion is designed to be candid and clinically grounded: where the evidence supports a change in practice, where it does not yet, and what an EP-ready screening workflow would actually look like.

This session will explore the transformative role of Ambulatory Surgery Centers (ASCs) in advancing cardiovascular care. Moderated by renowned experts, the discussion will highlight innovative strategies for incorporating ASCs into clinical practice, focusing on efficiency, patient outcomes, and cost-effectiveness, with insights from leading panelists shaping the future of cardiovascular surgery.

Robotic navigation, AI-assisted mapping, and automated lesion delivery are redefining procedural EP. This forward-looking session examines the feasibility, safety, and workflow transformation of semi-autonomous and autonomous EP labs.

As Pulse Field Ablation (PFA) becomes increasingly adopted, optimizing post-procedural care is critical to improving long-term patient outcomes. Panelists will share real-world experiences and discuss how remote cardiac monitoring and AI-driven insights can help identify arrhythmia recurrence, personalize follow-up strategies, and inform anticoagulation management decisions. Attendees will gain practical perspectives on emerging approaches to delivering more data-driven, patient-centered care after PFA.

Overcoming the challenges in remote monitoring, from patient engagement to billing, with shared best practices. Remote monitoring of CIEDs is widely adopted, but billing practices, compliance requirements, and documentation standards remain inconsistent and often misunderstood. This roundtable will focus on the practical realities of billing Medicare for CIED remote monitoring, including common pitfalls, audit risks, and how leading programs are structuring workflows to stay compliant. Attendees will leave with a clearer understanding of what is defensible, scalable, and aligned with current regulations.

Atrial fibrillation and heart failure represent a growing dual epidemic, each condition amplifying the progression and complexity of the other. This roundtable will explore the bidirectional pathophysiology linking AF and HF, examining evidence-based strategies for screening, rhythm and rate control, guideline-directed medical therapy, and device-based approaches. Participants will leave with a sharper framework for managing this high-risk patient population across the full spectrum of heart failure phenotypes.

As cardiovascular care becomes increasingly digital, health systems are seeking ways to unify data from medical devices, electronic medical records, remote monitoring programs, AI tools, and patient engagement platforms. An intelligent cardiology platform can streamline workflows, improve clinical decision-making, and create a more connected patient experience. This roundtable will explore strategies, challenges, and best practices for building an integrated ecosystem that supports scalable, data-driven cardiovascular care. Question being answered: How do we build the connected platform that makes AI, remote monitoring, and patient engagement work together?

Reducing delays in healthcare is needed now more than ever. With growing demand and limited EP capacity, getting patients through to the right care is key. In this roundtable session, clinicians will explore what is needed in cardiac data, and how it should be delivered, to help them confidently move patients forward.

Retail wearable arrhythmia devices are becoming more frequently used by both arrhythmia patients and by individuals with no antecedent cardiac history. Management approaches to address detected abnormalities or potential abnormalities remain a work in progress. In this session we will engage a broad-based faculty to identify the major concerns and discuss possible best practice solutions.

The HRX 2026 Pitch Competition provides cardiovascular startups with a platform to present their innovative products, services, and solutions to a distinguished panel of judges and potential investors and win cash prices. The top ten teams selected will compete on the HRX Main Stage. Each team will have ~5-10 minutes to creatively pitch their innovative idea, followed by five minutes to field questions from judges and attendees.

This session is a focused comparison of lesion biology, workflow, and safety across PFA platforms.

The next generation of cardiovascular intelligence depends on access to high-quality, structured clinical data. This session will examine how structured discrete data can support machine learning development, improve risk prediction, advance interoperability, and help clinicians track patient trajectories over time to drive earlier interventions and better outcomes.

XR/AR in Cardiac Ablation This session will explore the current and future clinical utility of extended and augmented reality in the EP lab — from holographic cardiac mapping to the virtualization of procedural screens — examining where the technology delivers measurable value and what barriers, including hardware and headset form factor, must still be overcome.

We aren’t just changing the tool; we are changing the physics of the procedure. By moving to programmable platforms, we give the electrophysiologist the ‘knobs’ to tune therapy in real-time, moving EP from a practiced art to a precise science.

Continuing the interoperability conversation: how to achieve comprehensive cardiovascular patient care through unification and integration of disparate data sources. CIED, Heart Failure, remote physiologic data, wearables, plus what is in the future? Moving from episodic care to streaming care. How will AI play into this and how can informed digital literacy help us?

As ECG and rhythm data becomes more abundant, accessible, and AI-enabled, electrophysiologists face new questions about trust, actionability, and workflow. The choices of monitoring from single time to fixed uninterrupted, to indefinite interrupted — each with its own technical, clinical, and patient-centered tradeoffs. For example, while trials have shown safety using 48-hour Holter for cessation of post-ablation anticoagulation, their sensitivity is reduced compared to more extended monitoring.
This roundtable will examine what types of monitoring to use, to guide major decisions such as stopping oral anticoagulation, how consumer ECGs and wearables are changing the need for prescribed diagnostic monitors, tradeoffs of positive predictive value based on AI and monitor, and represents an appropriate standard of care given that sensitivity and accuracy will vary based on tool and technology. We will also discuss the impact of clinical decision support tools and opportunities for clinical decision making to occur upstream of EP.

This session critically examines AI-powered decision algorithms in healthcare—where they help, where they harm, and what it takes to use them responsibly. We’ll explore real-world examples across triage, diagnosis, risk prediction, and treatment recommendations, highlighting evidence on accuracy, bias, explainability, and clinical impact. Participants will debate key “pro vs. con” questions: Do algorithms improve outcomes or add noise? Who is accountable when AI is wrong? How do we protect privacy while enabling learning health systems? The session also covers practical governance (validation, monitoring, human-in-the-loop workflows, and regulatory considerations) and offers a checklist for evaluating AI tools before deployment in clinical practice.

The landscape of connected care is rapidly changing, where patient data flows across devices, platforms, and care teams in real time. We will explore how emerging interoperability standards are reshaping the way physicians and nurses access and act on cardiac and chronic disease data — without sacrificing privacy, security, or clinical accuracy. Join us for a candid conversation on what responsible innovation actually looks like at the bedside, and how the tools being built today can either earn your trust.

Few electrophysiologists have shaped the field as deeply or as repeatedly as Professor Michel Haïssaguerre. Best known for the seminal discovery that pulmonary vein triggers initiate atrial fibrillation, a finding that transformed AF from a largely medical disease into an ablation target, his contribution extends far beyond a single landmark observation.

Across his career, Professor Haïssaguerre has been at the forefront of the ideas, techniques and technologies that now define daily electrophysiology practice. His work helped establish curative catheter ablation for AVNRT and AVRT, advanced the mechanistic understanding and ablation of ventricular fibrillation, and the recognition of early repolarisation syndromes. He has also been closely linked to the development and clinical adoption of tools that changed how electrophysiologists see and treat arrhythmias, including circular pulmonary vein mapping, and multipolar mapping technologies such as the PentaRay catheter. More recently focused on non-invasive mapping to improve our understanding of arrhythmia mechanisms.
In this main tent conversation, Professor Haïssaguerre joins Professor Prashanthan Sanders to reflect on a career defined by clinical observation, scientific courage and technological innovation. The discussion will trace how disruptive ideas move from the laboratory and catheterisation laboratory into global standards of care: from the early days of supraventricular tachycardia ablation, through the pulmonary vein discovery in AF, to ventricular fibrillation mapping, inherited arrhythmia syndromes, and the next frontiers in ablation science.

This session offers attendees a rare opportunity to hear from one of the defining innovators of modern electrophysiology, not only about the discoveries that changed the field, but about the mindset required to make them.

While EP labs are equipped with advanced imaging, mapping, and procedural technologies, integrating these systems into a seamless workflow remains a challenge in practice. This panel will explore how today’s multimodality environments function during real procedures and where connectivity works, where it falls short, and what true coordination across systems should look like to support complex ablation cases.

How innovators navigate FDA, evidence expectations, and payer realities.

Where CNA fits today and how the field should define success.

Electrophysiology is entering a new era where mapping must do more than reconstruct chambers and display voltage. This roundtable will explore how AI, advanced imaging, tissue characterization, signal clarity, and lesion assessment can reshape the future of cardiac mapping, including how mapping can better define substrate, reduce ambiguity, and help assess therapy effect in the era of PFA. The discussion will also address what next generation mapping platforms need to support clinically and technically, from smarter imaging integration to connected workflows that make procedural intelligence more actionable.